title: [Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice].
abstract: Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months. The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months. Later on, Epitalon-treated mice revealed distinct inhibition of carcinogenesis. One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05). Two or more tumors per animal were in 75%, 95% and 56%, respectively (p < 0.05). Largest diameter of mammary adenocarcinoma in the Epitalon group was smaller than in controls by 33% (p < 0.05). Although the number of mice with metastases to the lung in all three groups was practically identical, their incidence in the Vilon group was 2.6 times higher than in Epitalon-treated animals (p < 0.05). Largest diameter of metastasis in the Epitalon group was the smallest, too. Our data point to inhibition of mammary carcinogenesis by Epitalon in transgenic erbB-2/neu mice.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
authors.forename: I N
authors.initials: IN
authors.lastname: Alimova
authors.forename: D A
authors.initials: DA
authors.lastname: Bashurin
authors.forename: I G
authors.initials: IG
authors.lastname: Popovich
authors.forename: M A
authors.initials: MA
authors.lastname: Zabezhinskiĭ
authors.forename: M A
authors.initials: MA
authors.lastname: Volkov
authors.forename: M
authors.initials: M
authors.lastname: Provinciali
authors.forename: C
authors.initials: C
authors.lastname: Franceschi
authors.forename: B Kh
authors.initials: BKh
authors.lastname: Khavincon
authors.forename: V N
authors.initials: VN
authors.lastname: Anisimov
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000517:prevention & control*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D004151:Dipeptides / Q000627:therapeutic use*; D005260:Female; D018734:Genes, erbB-2; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D009842:Oligopeptides / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D004151:Dipeptides; D009842:Oligopeptides; C415909:lysylglutamic acid; C421253:alanyl-glutamyl-aspartyl-glycine